Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Acquires 25,000 Shares

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 25,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was bought at an average cost of $1.96 per share, with a total value of $49,000.00. Following the purchase, the director owned 461,904 shares of the company’s stock, valued at $905,331.84. This represents a 5.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Wednesday, July 8th, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The shares were purchased at an average price of $1.99 per share, for a total transaction of $39,800.00.
• On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $2.05 per share, for a total transaction of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The stock was purchased at an average price of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were purchased at an average cost of $1.98 per share, with a total value of $39,600.00.

Palisade Bio Stock Performance

Shares of Palisade Bio stock traded down $0.01 on Friday, reaching $1.96. 3,452,719 shares of the stock were exchanged, compared to its average volume of 4,494,371. The firm has a market cap of $340.22 million, a PE ratio of -1.94 and a beta of 1.50. The firm’s 50 day moving average is $1.92 and its 200-day moving average is $1.92. Palisade Bio, Inc. has a one year low of $0.53 and a one year high of $2.85.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, equities research analysts expect that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Palisade Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. CTC Alternative Strategies Ltd. bought a new position in Palisade Bio in the first quarter valued at about $31,000. Bank of America Corp DE grew its holdings in shares of Palisade Bio by 181.1% during the first quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock worth $345,000 after purchasing an additional 126,977 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Palisade Bio by 1.4% during the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after purchasing an additional 149,118 shares during the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Palisade Bio by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock worth $3,963,000 after purchasing an additional 260,000 shares during the last quarter. Finally, Orbimed Advisors LLC increased its stake in shares of Palisade Bio by 24.7% in the first quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock valued at $4,083,000 after buying an additional 461,580 shares during the period. Institutional investors own 11.79% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on PALI. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Oppenheimer set a $7.00 price objective on Palisade Bio in a research note on Tuesday, June 30th. Wolfe Research started coverage on Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Finally, LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $8.83.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.